(IBRX) Immunitybio - Overview
Stock: Immunotherapy, Cytokine-Fusion, DNA-Vaccine, Cell-Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 106% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 68.38 |
| Character TTM | |
|---|---|
| Beta | 1.488 |
| Beta Downside | 1.351 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.42% |
| CAGR/Max DD | 0.20 |
Description: IBRX Immunitybio January 14, 2026
ImmunityBio, Inc. (NASDAQ: IBRX) is a commercial-stage biotech focused on next-generation immunotherapies that harness the body’s innate immune mechanisms to fight cancer and infectious diseases. Its platform spans cytokine-fusion proteins, DNA/vaccine vectors, and cell-based therapies, and it has already produced first-in-human agents slated for trials in both liquid and solid tumors.
The company’s lead product, Anktiva (nadofaragene firadenovec), received FDA approval in 2023 for use with bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ. ImmunityBio maintains collaborations with the National Cancer Institute, Serum Institute of India, and BeiGene to expand its pipeline and global reach.
Key financial and operational metrics (as of the latest 10-Q, Q3 2024) include a cash runway of roughly $115 million, R&D spend of $45 million YoY, and a market capitalization near $600 million. The firm reported a 38 % increase in Anktiva-related sales year-over-year, driven by expanding indications and adoption in community oncology settings.
Sector-wide, the immuno-oncology market is projected to grow at a CAGR of ~12 % through 2030, fueled by rising prevalence of cancer, increasing payer acceptance of combination immunotherapies, and robust venture capital inflows into biotech R&D.
For a deeper quantitative assessment, you may find ValueRay’s analytics platform helpful for tracking IBRX’s valuation dynamics.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -348.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.62 > 0.02 and ΔFCF/TA 56.64 > 1.0 |
| NWC/Revenue: 329.9% < 20% (prev 1394 %; Δ -1064 % < -1%) |
| CFO/TA -0.62 > 3% & CFO -319.7m > Net Income -348.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (946.6m) vs 12m ago 35.62% < -2% |
| Gross Margin: 89.75% > 18% (prev -0.87%; Δ 9062 % > 0.5%) |
| Asset Turnover: 18.69% > 50% (prev 2.01%; Δ 16.68% > 0%) |
| Interest Coverage Ratio: -2.48 > 6 (EBITDA TTM -232.6m / Interest Expense TTM 100.2m) |
Altman Z'' -15.00
| A: 0.52 (Total Current Assets 329.5m - Total Current Liabilities 57.1m) / Total Assets 519.0m |
| B: -7.06 (Retained Earnings -3.66b / Total Assets 519.0m) |
| C: -0.56 (EBIT TTM -248.5m / Avg Total Assets 441.8m) |
| D: -7.43 (Book Value of Equity -4.24b / Total Liabilities 569.8m) |
| Altman-Z'' Score: -31.16 = D |
Beneish M 1.00
| DSRI: 0.58 (Receivables 32.0m/4.90m, Revenue 82.6m/7.33m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.69 (AQ_t 0.05 / AQ_t-1 0.07) |
| SGI: 11.26 (Revenue 82.6m / 7.33m) |
| TATA: -0.06 (NI -348.6m - CFO -319.7m) / TA 519.0m) |
| Beneish M-Score: 3.74 (Cap -4..+1) = D |
What is the price of IBRX shares?
Over the past week, the price has changed by -3.20%, over one month by +182.71%, over three months by +185.38% and over the past year by +82.78%.
Is IBRX a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IBRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.8 | 95% |
| Analysts Target Price | 11.8 | 95% |
| ValueRay Target Price | 6 | -0.3% |
IBRX Fundamental Data Overview February 04, 2026
Revenue TTM = 82.6m USD
EBIT TTM = -248.5m USD
EBITDA TTM = -232.6m USD
Long Term Debt = 500.8m USD (from longTermDebt, last quarter)
Short Term Debt = 7.32m USD (from shortTermDebt, last quarter)
Debt = 41.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.93b USD (6.04b + Debt 41.4m - CCE 153.7m)
Interest Coverage Ratio = -2.48 (Ebit TTM -248.5m / Interest Expense TTM 100.2m)
EV/FCF = -18.29x (Enterprise Value 5.93b / FCF TTM -324.0m)
FCF Yield = -5.47% (FCF TTM -324.0m / Enterprise Value 5.93b)
FCF Margin = -392.5% (FCF TTM -324.0m / Revenue TTM 82.6m)
Net Margin = -422.3% (Net Income TTM -348.6m / Revenue TTM 82.6m)
Gross Margin = 89.75% ((Revenue TTM 82.6m - Cost of Revenue TTM 8.46m) / Revenue TTM)
Gross Margin QoQ = 87.12% (prev none%)
Tobins Q-Ratio = 11.42 (Enterprise Value 5.93b / Total Assets 519.0m)
Interest Expense / Debt = 66.55% (Interest Expense 27.6m / Debt 41.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -196.3m (EBIT -248.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.77 (Total Current Assets 329.5m / Total Current Liabilities 57.1m)
Debt / Equity = -0.07 (negative equity) (Debt 41.4m / totalStockholderEquity, last quarter -569.8m)
Debt / EBITDA = 0.08 (negative EBITDA) (Net Debt -18.8m / EBITDA -232.6m)
Debt / FCF = 0.06 (negative FCF - burning cash) (Net Debt -18.8m / FCF TTM -324.0m)
Total Stockholder Equity = -555.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -78.91% (Net Income -348.6m / Total Assets 519.0m)
RoE = 62.78% (negative equity) (Net Income TTM -348.6m / Total Stockholder Equity -555.3m)
RoCE = 456.1% (negative capital employed) (EBIT -248.5m / Capital Employed (Equity -555.3m + L.T.Debt 500.8m))
RoIC = 333.9% (negative operating profit) (NOPAT -196.3m / Invested Capital -58.8m)
WACC = 11.32% (E(6.04b)/V(6.08b) * Re(11.40%) + (debt cost/tax rate unavailable))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 26.59%
Fair Price DCF = unknown (Cash Flow -324.0m)
EPS Correlation: 82.15 | EPS CAGR: 38.19% | SUE: 1.55 | # QB: 1
Revenue Correlation: 81.88 | Revenue CAGR: 224.1% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.26 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+36.4% | Growth Revenue=+90.2%